Abstract:Sarcopenia is a skeletal muscle disease that often manifests with aging, characterized in part by low skeletal muscle strength and mass as well as low physical performance (i.e., exercise intolerance) compared to young adults, which contributes to increased frailty. There remains a need to develop novel and adherable interventions for mitigating these losses with aging. Increased flavonoid consumption is inversely related to frailty in mid-life/older adults. Late-life oral supplementation with the natural flavonoid apigenin can improve select age-related conditions; however, its effect on treating features of sarcopenia is unkown. Hypothesis. We hypothesized that late-life oral supplementation with apigenin would result in greater grip strength and skeletal muscle mass, increased exercise tolerance, and lower frailty with aging. Methods. Young (Y; 6 mo) and old (O; 27 mo) male C57BL/6N mice consumed drinking water containing vehicle (control [C]; 0.2% carboxymethylcellulose; YC, n=10; OC, n=7) or apigenin (Api; 0.5 mg/mL in vehicle; Y-Api, n=10; O-Api, n=9]) for 6 weeks. Skeletal muscle strength was measured by forelimb grip strength. Skeletal muscle mass was assessed as quadriceps weight relative to body mass. Exercise tolerance was determined using a rota-rod and quantified as time spent running while the rota-rod accelerated from 50-100% of maximal running speed. Frailty was evaluated using a validated frailty index. Exercise tolerance was assessed before and after the intervention, and skeletal muscle strength, mass, and frailty were quantified at the end of the intervention. Data are reported as mean±SEM. Results. Forelimb grip strength. Forelimb grip strength (g of force/bodyweight) was higher in YC vs. OC (6.7±0.3 vs 5.3±0.2, P=0.001) and in O-Api (6.1±0.2, P=0.006 vs OC). However, O-Api was still lower than Y-Api (YApi, 6.9±0.3, P=0.025 vs O-Api). There were no differences between Y-Api and YC ( P=0.520). Quadriceps mass. Quadriceps mass (mg/bodyweight) was higher in YC vs OC (9.5±0.6 vs 7.8±0.4, P=0.051), in O-Api vs OC (O-Api, 9.9±0.6; P=0.005 vs OC), and in Y-Api vs YC (11.1±0.5, P =0.064 vs YC). O-Api was not different than Y-Api ( P=0.111). Exercise tolerance. Prior to the intervention we observed differences with aging (YC, 1233±141 sec vs OC, 614±128 sec; P=0.010), but no differences between treatment groups (YC vs Y-Api, P=0.115; OC vs O-Api, P=0.177). Following the intervention, exercise tolerance was increased in the O-Api group (pre: 443±50 sec vs post: 1118±113 sec, P<0.001) but unchanged in other groups ( P=0.137-0.543). Frailty. Frailty index was higher in OC vs YC (0.24±0.02 vs 0.02±0.01, P<0.001). Frailty in O-Api mice was higher than Y-Api (0.18±0.01 vs 0.02±0.01 P<0.001), but lower than OC ( P=0.005). There were no differences between Conclusions. Oral supplementation with apigenin may be an effective therapeutic strategy to treat select characteristics of sarcopenia and associated frailty with aging. NIH AG055822-02S1, K99 HL159241, H2020-MSCA-IF-2019: 892267, T32 DK007135 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Restorative effects of (+)-epicatechin in a rodent model of aging induced muscle atrophy: underlying mechanisms

EFFECTS OF FLAVANOL (+)-EPICATECHIN ON SKELETAL MUSCLE OF AGED RATS

Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia

Challenging Sarcopenia: Exploring AdipoRon in Aging Skeletal Muscle as a Healthspan-Extending Shield

Effect of Epicatechin on Skeletal Muscle

Improvement in Skeletal Muscle Strength and Plasma Levels of Follistatin and Myostatin Induced by an 8-Week Resistance Training and Epicatechin Supplementation in Sarcopenic Older Adults

Synergistic Effects of MFG-E8 and Whey Protein on Mitigating D-Galactose-induced Sarcopenia Through PI3K/AKT/PGC-1α and MAPK/ERK Signaling Pathways

Beneficial Effects of a Mixture of Algae and Extra Virgin Olive Oils on the Age-Induced Alterations of Rodent Skeletal Muscle: Role of HDAC-4

(−)-Epicatechin treatment modify the expression of genes related to atrophy in gastrocnemius muscle of male rats obese by programing

Protective Effects of Cervus elaphus and Eucommia ulmoides Mixture (KGC01CE) on Muscle Loss and Function in Aged Rats

The exerkine apelin reverses age-associated sarcopenia

Restorative potential of (-)-epicatechin in a rat model of Gulf War illness muscle atrophy and fatigue

Dietary epicatechin improves survival and delays skeletal muscle degeneration in aged mice

The Panax ginseng Berry Extract and Soluble Whey Protein Hydrolysate Mixture Ameliorates Sarcopenia-Related Muscular Deterioration in Aged Mice

Beneficial Effects of (−)‐Epicatechin on Biomarkers of Endothelial Cell Aging

Endothelin-1 induces cellular senescence and fibrosis in cultured myoblasts. A potential mechanism of aging-related sarcopenia

Late-life oral supplementation with apigenin mitigates loss of skeletal muscle strength and mass, exercise intolerance, and frailty with aging in mice

New Trends to Treat Muscular Atrophy: A Systematic Review of Epicatechin

Potential nutritional strategies to prevent and reverse sarcopenia in aging process: Role of fish oil-derived ω-3 polyunsaturated fatty acids, wheat oligopeptide and their combined intervention

Restoration of epigenetic impairment in the skeletal muscle and chronic inflammation resolution as a therapeutic approach in sarcopenia